Vericel Revenue Growth Rates (VCEL), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Vericel Corporation  (NASDAQ: VCEL)
 

VCEL's Revenue Growth by Quarter and Year

Vericel's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/VCEL/growth
https://api.csimarket.com/api/v1/companies/VCEL/fundamentals
https://api.csimarket.com/api/v1/companies/VCEL/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery
Connect Your AI Assistant
How to Connect Your AI Assistant to CSIMarket MCP MCP Server
Access this full dataset via API
Free sample Full docs All endpoints
VCEL Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 85.37
2nd Quarter June 77.46
1st Quarter March 68.43
FY 231.26

VCELs Annual Revenue
Vericel's Revenue in the fiscal year 2025 $ 276.26 millions
Vericel's Revenue in the fiscal year 2024 $ 237.22 millions
Vericel's Revenue in the fiscal year 2023 $ 197.52 millions
Vericel's Revenue in the fiscal year 2022 $ 164.37 millions
Vericel's Revenue in the fiscal year 2021 $ 156.18 millions




VCEL Revenue third quarter 2026 Y/Y Growth Comment
Vericel Corporation reported Revenue improvement of 26.48% year on year in the third quarter 2026, to $ 85.37 millions, this is lower than Vericel Corporation's recent average Revenue surge of 6391.99%.

Looking into third quarter 2026 results within Biotechnology & Pharmaceuticals industry 28 other companies have achieved higher Revenue growth. While Vericel Corporation' s Revenue rise of 26.48% ranks overall at the positon no. 947 in the third quarter 2026.


VCEL Revenue ( Y/Y Growth %) 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 26.48 %
2nd Quarter June 22.49 %
1st Quarter March 30.1 %
FY   -

Financial Statements
Vericel's third quarter 2026 Revenue $ 85.37 millions VCEL's Income Statement
Vericel's third quarter 2025 Revenue $ 67.50 millions Quarterly VCEL's Income Statement


VCEL Revenue (Quarter on Quarter Growth %)

 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 10.21 %
2nd Quarter June 13.2 %
1st Quarter March -26.36 %
FY (Year on Year)   -


Back to VCEL Growth rate Comparisons >> Back to VCEL Growth rate Comparisons >>


Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #29
Healthcare Sector #193
Overall #947

Revenue Y/Y Growth Statistics
High Average Low
183725 % 6391.99 % -100 %
(Dec 31 2018)   (Jun 30 2022)
Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #29
Healthcare Sector #193
Overall #947
Revenue Y/Y Growth Statistics
High Average Low
183725 % 6391.99 % -100 %
(Dec 31 2018)   (Jun 30 2022)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Vericel's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
117.92 % -1.71 % -100 %
(Sep 30 2014)  


VCEL's III. Quarter Q/Q Revenue Comment
Vericel Corporation achieved in the III. Quarter 2026 above company average sequential Revenue rise of 10.21%, to $ 85.37 millions, from $77.46 millions in the second quarter.

Within Biotechnology & Pharmaceuticals industry 16 other companies have achieved higher Revenue quarter on quarter growth. While Vericel's Revenue growth quarter on quarter, overall rank is 698.


Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #17
Healthcare Sector #117
Overall #698
Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #17
Healthcare Sector #117
Overall #698
Revenue Q/Q Growth Statistics
High Average Low
117.92 % -1.71 % -100 %
(Sep 30 2014)  


VCEL's III. Quarter Q/Q Revenue Comment
Vericel Corporation achieved in the III. Quarter 2026 above company average sequential Revenue rise of 10.21%, to $ 85.37 millions, from $77.46 millions in the second quarter.

Within Biotechnology & Pharmaceuticals industry 16 other companies have achieved higher Revenue quarter on quarter growth. While Vericel's Revenue growth quarter on quarter, overall rank is 698.


Vericel's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)		 12 Months Ending (Mar 31 2026) 12 Months Ending (Dec 31 2025) 12 Months Ending (Sep 30 2025) 12 Months Ending (Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 306.30
Y / Y Revenue Growth (TTM) 22.95 %
Year on Year Revenue Growth Overall Ranking # 1056
Seqeuential Revenue Change (TTM) 4.87 %
Seq. Revenue Growth (TTM) Overall Ranking # 2144


Cumulative Revenue growth Comment
Vericel saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 22.95% year on year, to $ 306 millions if the fiscal year would have ended in Jun 30 2026.
Vericel's trailing twelve months Revenue growth was higher than company's average 19.01% and higher than 22.45% growth in Mar 31 2026.
But from twelve months ended Mar 31 2026 rise was beneth at 4.87 % from $292.09 millions achieved in the period from Mar 31 2026 to Jun 30 2025.
We witness drop-off happening, more obvious observing the usual Q/Q TTM historic rise that is stronger at19.01%.

In the Healthcare sector 203 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 903 to 1056.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 35
Healthcare Sector # 204
Overall # 1056

Revenue TTM Y/Y Growth Statistics
High Average Low
42.13 %
 19.01 %
2.4 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 35
Sector # 317
S&P 500 # 2144
Cumulative Revenue growth Comment
Vericel saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 22.95% year on year, to $ 306 millions if the fiscal year would have ended in Jun 30 2026.
Vericel's trailing twelve months Revenue growth was higher than company's average 19.01% and higher than 22.45% growth in Mar 31 2026.
But from twelve months ended Mar 31 2026 rise was beneth at 4.87 % from $292.09 millions achieved in the period from Mar 31 2026 to Jun 30 2025.
We witness drop-off happening, more obvious observing the usual Q/Q TTM historic rise that is stronger at19.01%.
The momentum is even more impressive from twelve months ended Mar 31 2026 exhibited at 4.87 % increase from $292.09 millions in the period from Mar 31 2026 to Jun 30 2025.

In the Healthcare sector 203 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 903 to 1056.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 35
Healthcare Sector # 204
Overall # 1056

Revenue TTM Y/Y Growth Statistics
High Average Low
42.13 %
19.01 %
2.4 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 35
Sector # 317
S&P 500 # 2144




Other Revenue Growth
Biotechnology & Pharmaceuticals Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
VCEL's Revenue Growth Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue rise for the quarter ending Sep 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2026
Arcutis Biotherapeutics Inc 45.05%$ 45.052 millions
Zevra Therapeutics Inc 44.86%$ 44.864 millions
Xeris Biopharma Holdings Inc 44.16%$ 44.158 millions
Nephros Inc 43.60%$ 43.602 millions
Cardiff Oncology Inc 42.50%$ 42.500 millions
Neurocrine Biosciences Inc 41.24%$ 41.238 millions
Transmedics Group Inc 41.15%$ 41.149 millions
Uniqure N v 40.39%$ 40.394 millions
Harrow Inc 40.00%$ 40.001 millions
Mirum Pharmaceuticals Inc 39.63%$ 39.629 millions
Caredx Inc 39.29%$ 39.285 millions
Halozyme Therapeutics Inc 39.15%$ 39.154 millions
Eli Lilly And Company38.61%$ 38.613 millions
Myomo Inc 37.42%$ 37.416 millions
Editas Medicine Inc 37.41%$ 37.412 millions
Beyond Air Inc 36.55%$ 36.545 millions
Clearpoint Neuro Inc 36.27%$ 36.271 millions
Regeneron Pharmaceuticals Inc 36.27%$ 36.265 millions
Travere Therapeutics Inc 36.22%$ 36.215 millions
Omada Health Inc 36.13%$ 36.133 millions
Guardant Health Inc 36.12%$ 36.116 millions
Natera Inc 34.08%$ 34.077 millions
Establishment Labs Holdings Inc 34.08%$ 34.075 millions
Beone Medicines Ltd 33.86%$ 33.861 millions
Ceribell Inc 33.72%$ 33.721 millions
Zomedica Corp 33.12%$ 33.123 millions
Intuitive Surgical Inc 32.71%$ 32.714 millions
Adc Therapeutics Sa32.20%$ 32.197 millions
Biomarin Pharmaceutical Inc32.02%$ 32.019 millions
The Pennant Group Inc 31.96%$ 31.965 millions


About Vericel Revenue Growth Rates (VCEL), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Vericel Corp (CIK 887359).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001628280-26-070657
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Vericel Corp’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.